201 related articles for article (PubMed ID: 37971628)
1. Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.
Yao G; Yuan J; Duan Q; Tan Y; Zhang Q; Chen D; Chen J
Invest New Drugs; 2024 Feb; 42(1):1-13. PubMed ID: 37971628
[TBL] [Abstract][Full Text] [Related]
2. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.
Wu YX; Zhou XY; Wang JQ; Chen GM; Chen JX; Wang RC; Huang JQ; Chen JS
Immunotherapy; 2023 Feb; 15(2):101-115. PubMed ID: 36597704
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.
Li S; Xu Q; Dai X; Zhang X; Huang M; Huang K; Shi D; Wang J; Liu L
Ann Surg Oncol; 2023 Jun; 30(6):3594-3602. PubMed ID: 36795255
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.
Li S; Yu W; Xie F; Luo H; Liu Z; Lv W; Shi D; Yu D; Gao P; Chen C; Wei M; Zhou W; Wang J; Zhao Z; Dai X; Xu Q; Zhang X; Huang M; Huang K; Wang J; Li J; Sheng L; Liu L
Nat Commun; 2023 Jan; 14(1):8. PubMed ID: 36596787
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].
Zhu ZG
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1331-1336. PubMed ID: 38644278
[TBL] [Abstract][Full Text] [Related]
7. Advances in clinical immunotherapy for gastric cancer.
Li K; Zhang A; Li X; Zhang H; Zhao L
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
9. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability-High Gastric Cancer: A Case Series.
Liu L; Woo Y; D'Apuzzo M; Melstrom L; Raoof M; Liang Y; Afkhami M; Hamilton SR; Chao J
J Natl Compr Canc Netw; 2022 Aug; 20(8):857-865. PubMed ID: 35948034
[TBL] [Abstract][Full Text] [Related]
15. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers.
Baxter MA; Middleton F; Cagney HP; Petty RD
Br J Cancer; 2021 Oct; 125(8):1068-1079. PubMed ID: 34230609
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress.
Song X; Qi W; Guo J; Sun L; Ding A; Zhao G; Li H; Qiu W; Lv J
Oncol Lett; 2020 Oct; 20(4):46. PubMed ID: 32802168
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer: A Review.
Emiloju OE; Sinicrope FA
JAMA Oncol; 2023 Dec; 9(12):1708-1715. PubMed ID: 37676680
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
